Pfizer Inc. (PFE) Drops 3.47% After Earnings

2026-02-03 · Stocks · QuoteReporter

Post Earning Analysis

Pfizer Inc. (PFE) Drops 3.47% After Earnings

Pfizer Inc. is a leading research-based global biopharmaceutical company established in 1849 by Charles Pfizer Sr. and Charles Erhart. Headquartered in New York, NY, Pfizer focuses on the development, manufacture, and distribution of innovative medical solutions worldwide. The company is dedicated to improving health by advancing treatments and cures for some of the most challenging diseases.

Pfizer’s stock has experienced significant fluctuations following a series of news releases on February 3, 2026. The pharmaceutical giant reported a quarterly loss, contributing to a drop in share prices. Despite the overall loss, Pfizer managed to beat quarterly estimates, which could indicate underlying resilience in its operations. However, the company’s revenue projections for 2026 are less optimistic, largely due to anticipated patent losses, which could weigh on future earnings.

Additionally, Pfizer’s stock was negatively impacted by data from an obesity-drug study, which showed only a 13% weight loss, leading to further declines in stock value. This news is particularly impactful as the obesity treatment market is highly competitive and expectations were high for Pfizer’s entry into this space. The company has reaffirmed its modest outlook for the fiscal year, suggesting a cautious approach amidst these challenges.

Investors and analysts will likely continue to watch Pfizer closely, as its performance in the coming quarters will be critical in determining the long-term impact of these developments on its financial health and stock performance.

The current price of the asset is $25.72, marking a significant daily decrease of 3.47%. This drop positions the price closer to the lower end of the weekly range ($25.26 – $26.69) and suggests a potential short-term bearish sentiment. Despite today’s decline, the asset shows a robust recovery from its 52-week and year-to-date lows of $19.5, reflecting a 31.9% increase, indicating strong medium to long-term bullish momentum.

The moving averages (MA) analysis further supports this, with the price exceeding the 20-day MA by 0.81%, the 50-day MA by 2.18%, and the 200-day MA by a substantial 8.0%. This alignment above all key MAs typically signals a positive trend.

However, the Relative Strength Index (RSI) at 52.56 and the MACD at 0.35 suggest a more neutral stance in the immediate term, neither overbought nor oversold, and a slight positive momentum, respectively. The proximity to the 52-week high of $26.83 (only a 4.14% difference) might limit upward movements unless further positive catalysts occur. Overall, while today’s drop is notable, the broader indicators suggest a generally healthy upward trend with caution advised due to potential short-term volatility.

Pfizer Inc. reported its financial results for the fourth quarter and full year of 2025. The company saw a year-over-year operational revenue decline of 2% with total revenues reaching $62.6 billion for the year. Despite this, revenues excluding COVID-19 products like Paxlovid and Comirnaty grew by 6% operationally. The fourth quarter revenues were $17.6 billion, marking a 3% operational decline from the previous year, but excluding COVID contributions, there was a 9% operational increase.

Key product performances included significant growth in Pfizer’s biopharmaceuticals, with notable increases in Abrysvo (136%), oncology biosimilars (76%), and Lorbrena (45%). However, there were substantial declines in COVID-19 related products, with Comirnaty and Paxlovid seeing operational declines of 35% and 70%, respectively.

For the fourth quarter, the reported loss per share was $(0.29), while the adjusted diluted EPS was $0.66. The full year adjusted diluted EPS was reported at $3.22. Looking ahead to 2026, Pfizer anticipates revenues between $59.5 and $62.5 billion and an adjusted diluted EPS ranging from $2.80 to $3.00. The company also highlighted its significant investments in R&D and business development, totaling $10.4 billion and $8.8 billion respectively, and declared cash dividends of $9.8 billion, or $1.72 per share. No share repurchases were completed in 2025, with a remaining authorization of $3.3 billion for future repurchases.

Earnings Trend Table

The analysis of the quarterly EPS (Earnings Per Share) trends reveals a significant pattern of surpassing estimates consistently over the observed periods. Starting from the third quarter of 2023, there is a noteworthy transition from a negative EPS, where the reported EPS of -0.17 in Q3 2023 was a substantial improvement over the -0.34 estimate, indicating a less negative outcome than anticipated. This trend of positive surprises continues robustly into subsequent quarters.

By Q1 2024, the reported EPS not only exceeded the estimates but shifted from negative to positive figures, a remarkable turnaround as evidenced by the 145.84% surprise in reported EPS compared to the estimate. This positive trajectory is maintained through 2024, with each quarter showing significant improvements over the estimates, highlighted by the peak in Q4 2024, where the reported EPS of 1.06 vastly exceeded the 0.62 estimate with a 71.39% surprise.

The trend extends into 2025, with both Q1 and Q2 continuing to beat estimates by substantial margins. The consistent pattern of outperforming the EPS estimates suggests effective management strategies and potentially conservative estimation practices, or improving operational efficiencies and market conditions that favor the company’s financial outcomes. The data indicates strong financial health and the potential for continued positive performance.

Dividend Payments Table

The analysis of the dividend data over the specified period reveals a consistent trend in the distribution of dividends, with a notable adjustment in the amount. From May 2024 through November 2024, dividends were consistently set at $0.42. Starting from January 2025, there was a slight increase to $0.43, which has been maintained through to the latest recorded date in January 2026.

This increment, although modest, indicates a possible positive adjustment in the company’s dividend policy, reflecting either an improved financial performance or a strategic decision to return more capital to shareholders. The stability observed post-increase suggests a sustained confidence in the company’s earnings and cash flow stability, which is a positive signal to investors seeking reliable income streams. The maintenance of this dividend level over multiple quarters further reinforces the company’s commitment to a stable and possibly growing dividend payout.

In the analysis of the most recent rating changes for the company in question, we observe a series of evaluations from four different financial services firms over the course of approximately eight months.

1. UBS – January 7, 2026: UBS resumed coverage on the company, assigning a “Neutral” rating with a target price of $25. This suggests a cautious but not pessimistic outlook from UBS, indicating that the stock might perform in line with the general market expectations.

2. Citigroup – December 2, 2025: Shortly before UBS, Citigroup also resumed coverage with a “Neutral” rating, but set a slightly higher target price at $26. This minor difference in target price compared to UBS could reflect a marginally more optimistic view of the company’s financial health and market position, though still within the bounds of average market performance expectations.

3. Scotiabank – November 13, 2025: Scotiabank initiated coverage with a more bullish stance, rating the company as “Sector Outperform” with a target price of $30. This rating indicates that Scotiabank expects the company to perform better than other firms within the same sector, suggesting potential undervaluation or anticipated strong performance.

4. Cantor Fitzgerald – April 22, 2025: Earlier in the year, Cantor Fitzgerald initiated coverage with a “Neutral” rating and a target price of $24. This was the lowest target price among the recent ratings, suggesting a more conservative estimation of the company’s market trajectory compared to other analysts.

Overall, while most analysts (UBS, Citigroup, and Cantor Fitzgerald) are aligned with a neutral stance, indicating expected market-average performance, Scotiabank stands out with a more optimistic view. This divergence might reflect different analytical perspectives on the company’s growth potential or sector dynamics. The range of target prices ($24 to $30) also highlights varying expectations about the company’s financial future and stock performance.

The current price of the stock is $25.72, which is closely aligned with the average target price provided by various analysts. The target prices range from $24 to $30, with a mean target of approximately $26.25, suggesting a modest upside potential from the current market price.

The ratings from different analysts such as UBS, Citigroup, Scotiabank, and Cantor Fitzgerald vary slightly but predominantly lean towards a neutral stance with the exception of Scotiabank, which rates it as “Sector Outperform” with a target price of $30. This indicates a more optimistic view compared to others.

Unfortunately, the data provided does not include specific details on Earnings Per Share (EPS) trends or dividend policies, which are crucial for a comprehensive financial analysis. Therefore, investors should seek additional information on these aspects to better understand the financial health and profitability of the company, as well as its potential for income generation through dividends.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.